Press release - 05/07/2024 The Symphony of Organelles With "OrgaPlexing", scientists at the MPI of Immunobiology and Epigenetics have developed a new method that shows how guardian cells of the immune system, the macrophages, orchestrate their cell structures during inflammation or bacterial infection, making it possible to observe the interactions between several organelles simultaneously and thus providing insights into cell metabolism and the production of inflammatory molecules. https://www.gesundheitsindustrie-bw.de/en/article/press-release/symphony-organelles
Dossier - 20/12/2012 Medical technology serving healthcare Modern healthcare would be impossible without medical technology. The achievements in medical technology are indispensable for our health and quality of life. The range of medical technology available covers surgical instruments and implants to diagnostic methods and medical devices.https://www.gesundheitsindustrie-bw.de/en/article/dossier/medical-technology-serving-healthcare
Press release - 24/06/2024 Digital babies created to improve infant healthcare Researchers at University of Galway, the Heidelberg Institute for Theoretical Studies (HITS) Heidelberg University, and Heidelberg University Hospital have created digital babies to better understand infants’ health in their critical first 180 days of life. The international team created computer models that simulate the unique metabolic processes of each baby. The models can help to better understand rare metabolic diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/digital-babies-created-improve-infant-healthcare
Press release - 23/11/2021 Multi-peptide vaccine against SARS-CoV-2 shows strong T-cell immune response At the University Hospital Tübingen, clinical evaluation of an in-house developed vaccine (CoVac-1) against SARS-CoV-2 was started in November 2020 under the direction of Prof. Dr. Juliane Walz in the CCU Translational Immunology of the Medical Clinic (Medical Director Prof. Dr. Helmut Salih). Now the results of the Phase I study are available and demonstrate a potent activation of the T-cell response against the coronavirus.https://www.gesundheitsindustrie-bw.de/en/article/press-release/multi-peptide-vaccine-against-sars-cov-2-shows-strong-t-cell-immune-response
Press release - 01/03/2023 Pseudomonas aeruginosa Bacteria produce a molecule that paralyzes immune system cells Bacteria of the species Pseudomonas aeruginosa are antibiotic-resistant hospital germs that can enter blood, lungs and other tissues through wounds and cause life-threatening infections. In a joint project, researchers from the Universities of Freiburg and Strasbourg in France have discovered a mechanism that likely contributes to the severity of P. aeruginosa infections.https://www.gesundheitsindustrie-bw.de/en/article/press-release/pseudomonas-aeruginosa-bakterien-stellen-ein-molekuel-her-das-zellen-des-immunsystems-laehmt
Dossier - 13/05/2013 The human proteome the next major goal The “Human Proteome Project”, a ten-year global initiative that is making a systematic effort to map all human proteins, has moved from the planning to the experimental stage. How significant and how effective the project will be depends on how much the resources offered are used by proteome researchers and on the data that the researchers bring into the project.https://www.gesundheitsindustrie-bw.de/en/article/dossier/the-human-proteome-the-next-major-goal
Article - 28/03/2019 Supporting the human use of artificial intelligence Artificial intelligence is no longer a vision of the future, but is already in our midst: whether it is parking aids or search engines, we use the technology quite naturally in many areas of daily life. It promises new, unlimited opportunities, but also poses risks. Experts from the Integrata Foundation in Tübingen work on ethical issues and the human use of IT for improving the life of as many people as possible. https://www.gesundheitsindustrie-bw.de/en/article/news/supporting-the-human-use-of-artificial-intelligence
Press release - 05/03/2024 New Center for Synthetic Genomics Applying and developing new technologies for DNA synthesis to pave the way for producing entire artificial genomes – that is the goal of a new interdisciplinary center, 'Center for Synthetic Genomics', that is being established at Heidelberg University, Karlsruhe Institute of Technology (KIT), and Johannes Gutenberg University Mainz (JGU). https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-center-synthetic-genomics
Press release - 07/06/2024 German Research Foundation honors researchers for animal testing alternatives Prof. Dr. Peter Loskill and Dr. Silke Riegger from the 3R Center Tübingen for in-vitro models and animal testing alternatives have been awarded the Ursula M. Händel Animal Welfare Prize 2024. The prize, endowed with 80,000 euros, was awarded to them in Würzburg for the development of organ-on-chip (OoC) systems as an alternative to animal testing.https://www.gesundheitsindustrie-bw.de/en/article/press-release/german-research-foundation-honors-researchers-animal-testing-alternatives
Press release - 11/01/2023 Newly discovered surface structures may affect immune function Using new microscopic methods in combination with machine learning-based image analysis, researchers from Freiburg have discovered new structures on the surface of living B cells that affect the distribution and possibly the function of their antigen receptors. The researchers' study has been published in The EMBO Journal.https://www.gesundheitsindustrie-bw.de/en/article/press-release/newly-discovered-surface-structures-may-affect-immune-function
Press release - 25/05/2021 How “paralyzed” immune cells can be reactivated against brain tumors Brain tumor cells with a certain common mutation reprogram invading immune cells. This leads to the paralysis of the body's immune defense against the tumor in the brain. Researchers from Heidelberg, Mannheim, and Freiburg discovered this mechanism and at the same time identified a way of reactivating the paralyzed immune system to fight the tumor.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-paralyzed-immune-cells-can-be-reactivated-against-brain-tumors
Press release - 20/10/2022 Cytoskeleton acts as cells’ bouncer for bacteria Researchers of the University of Freiburg have discovered a previously unknown function of septins in defending cells against dangerous hospital pathogens.https://www.gesundheitsindustrie-bw.de/en/article/press-release/das-zellskelett-haelt-die-eintrittspforte-fuer-bakterien-geschlossen
Press release - 12/01/2023 “Zone of uncertainty” in the brain influences its ability to form new memories Researchers at the University of Freiburg Medical School led by Prof. Dr. Johannes Letzkus and the Max Planck Institute for Brain Research have discovered that a little-studied area of the brain, the "zone of uncertainty" or "zona incerta," communicates with the neocortex in unconventional ways to rapidly control memory formation.https://www.gesundheitsindustrie-bw.de/en/article/press-release/zone-der-ungewissheit-im-gehirn-beeinflusst-bildung-von-erinnerungen
Vaccine development - 25/05/2021 Vaccines - a beacon of hope in the fight against pandemics https://www.gesundheitsindustrie-bw.de/en/article/dossier/vaccines-beacon-hope-fight-against-pandemics
Press release - 10/06/2021 Nose2Brain – Active substances without detour through the nose into the brain Effective drugs for the treatment of diseases of the central nervous system do exist. However, the blood-brain barrier, which protects the brain as the body's control center, makes it especially difficult for therapeutic biomolecules to pass through. Thus, researchers from an international consortium coordinated by the Fraunhofer IGB have spent the last four and a half years developing a novel system in the EU project "N2B-patch"…https://www.gesundheitsindustrie-bw.de/en/article/press-release/nose2brain-active-substances-without-detour-through-nose-brain
Press release - 19/10/2022 Apogenix’ Asunercept Demonstrates Efficacy in Phase II Trial for the Treatment of Hospitalized COVID-19 Patients Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that asunercept showed statistically significant benefits for hospitalized COVID-19 patients in the ASUNCTIS trial. The open-label multi-center phase II trial investigated efficacy and safety of asunercept in 435 patients with moderate to severe COVID-19 disease.https://www.gesundheitsindustrie-bw.de/en/article/press-release/apogenixs-asunercept-zeigt-wirksamkeit-phase-ii-studie-zur-behandlung-von-covid-19-patienten-im-krankenhaus
Press release - 19/10/2022 Molecular structure of one of the most important receptors in the immune system unraveled Researchers from Freiburg and Harvard publish the three-dimensional structure of the B cell antigen receptor, shedding new light on its composition.https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-structure-one-most-important-receptors-immune-system-unraveled
Press release - 14/03/2024 Next milestone in the treatment of liver tumors and acute and chronic liver diseases The results of a Tuebingen-led study raise hope that a newly developed drug could herald a new era in oncological liver surgery and transplantation. The drug could even have the potential to significantly improve the treatment of acute and chronic liver diseases. The drug candidate "HRX-215" is a so-called MKK4 inhibitor, i.e. the drug inhibits the MKK4 protein found in liver cells and thus leads to an increase in the regeneration of…https://www.gesundheitsindustrie-bw.de/en/article/press-release/next-milestone-treatment-liver-tumors-and-acute-and-chronic-liver-diseases
Press release - 09/11/2022 New Molecular Microscopy Uncovers how Breast Cancer Spreads Researchers have created a tool that maps how breast cancer grows in previously unseen detail, and highlights how the cells around the tumour may be the key to controlling the spread of disease. The new technology can trace which populations of breast cancer cells are responsible for the spread of the disease, and for the first time highlights how the location of cancer cells could be as important as mutations in tumor growth The new study is…https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-molecular-microscopy-uncovers-how-breast-cancer-spreads
Dossier - 05/08/2013 Progress expands bioethical boundaries Bioethics is a rich and continually evolving field. In the broadest sense, bioethics relates to the way human individuals treat any form of life. The issue of whether human beings have the right to do whatever they want goes way back. Rapid progress in genetic engineering and cell biology means that it is necessary to look at certain issues in a new way and recognise that not everything that is technically feasible should actually be carried out.https://www.gesundheitsindustrie-bw.de/en/article/dossier/progress-expands-bioethical-boundaries
Dossier - 21/05/2013 No new drugs to be placed on the market without clinical trials New pharmaceuticals are subject to approval by drug authorities. Here clinical trials are performed to ensure the quality efficacy and safety of a medicinal product. Clinical development is a time-consuming and costly process and takes on average ten to fifteen years before a pharmaceutical company can apply for the approval of the drug. The costs including failures can amount to approximately one billion US dollars per drug.https://www.gesundheitsindustrie-bw.de/en/article/dossier/no-new-drugs-to-be-placed-on-the-market-without-clinical-trials
Press release - 05/07/2024 Outstanding ideas – new imaging processes for cancer diagnostics and nanopropellers for ocular gene therapy The summer reception hosted by BioRegio STERN Management GmbH has once again provided a fitting backdrop for the Science2Start award ceremony. Last Thursday, at Tübingen observatory, was the 15th time that scientists and start-up founders were celebrated for outstanding ideas that a panel of experts judged to have special economic potential.https://www.gesundheitsindustrie-bw.de/en/article/press-release/outstanding-ideas-new-imaging-processes-cancer-diagnostics-and-nanopropellers-ocular-gene-therapy
Dossier - 26/11/2012 Genetic diagnostics technology reaches the limits of what is medically reasonable Rapid progress in sequencing technologies is poised to set the imagination of biomedical researchers on fire. Experts now believe that progress is about to make possible what seemed to be utopian a few years ago – it seems likely that it will soon be possible to sequence the human genome in only a few minutes and store and automatically analyse it using tiny automates. However, is everything that is technically feasible also reasonable?https://www.gesundheitsindustrie-bw.de/en/article/dossier/genetic-diagnostics-technology-reaches-the-limits-of-what-is-medically-reasonable